Long-Acting Cabotegravir Plus Rilpivirine Noninferior To Daily Oral HIV Medication, Preferred By Most Patients, Trial Indicates

Healio (2/23, Stulpin) reports, “Long-acting cabotegravir plus rilpivirine administered every 2 months was noninferior to daily oral HIV medication and was preferred by most participants in a phase 3b randomized trial, according to data” presented at the...